A Randomized,Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants with Parkinson#s Disease

  • Slevin, John (PI)

Grants and Contracts Details


HUMAN CLINICAL TRIAL - CONFIDENTIAL To assess the safety and tolerability of the daily oral administration of nilotinib (150-300mg once daily) in moderate/advanced and early/de novo PD participants.
Effective start/end date11/7/179/17/19


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.